{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000064","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.332289+00:00","generated_at":"2026-05-31T23:28:28.975232+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1","bullets":["Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.","Drs. Keith Ward and Praveen Tyle resign from board effective Aug 1, 2024; no disagreement with company.","Grants new General Counsel Brennen Brodersen inducement award: option for 60,000 shares and 15,000 RSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000064","json":"https://secwatch.observer/filing/0001516551-24-000064.json","markdown":"https://secwatch.observer/filing/0001516551-24-000064.md","text":"https://secwatch.observer/filing/0001516551-24-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000064/0001516551-24-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000064/skye-20240701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:28:28.975232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cf9da2575","claim":"Keith Ward, PhD resigned as Director at Skye Bioscience, Inc..","evidence_excerpt":"On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000064/0001516551-24-000064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6b62b1350a","claim":"Karen L. Smith MD, PhD, MBA, LLM was appointed as Director at Skye Bioscience, Inc..","evidence_excerpt":"the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000064/0001516551-24-000064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6ca4adcbb4","claim":"Praveen Tyle, PhD resigned as Director at Skye Bioscience, Inc..","evidence_excerpt":"On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000064/0001516551-24-000064-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}